- 中文
- English
HW Biosciences
HW Biosciences develops ophthalmic devices with a primary focus on
the treatment of dry eye disease.
Your hindsight won't be the only 20/20 vision
Comfort with Every Blink™
HW Biosciences
HW Biosciences primarily focuses on the development of ophthalmic devices for the treatment of dry eye disease.
May every tear of yours be pure as the Heart Of Ocean
Comfort with Every Blink
About us
About us
HW Biosciences primarily focuses on developing technologies and devices for the treatment of dry eye disease.
HW Biosciences develops ophthalmic devices with a primary focus on the treatment of dry eye disease.
11.59
%
Global prevalence of dry eye disease was estimated at 11.59%
930
million
Dry eye disease affects more than 930 million people worldwide
86
%
Meibomian gland dysfunction accounts for 86% of dry eyes in the United States
11.59
%
Global prevalence of DED was estimated at 11.59%
660
million
Global dry eye treatments are expected to top over USD$6.6billion by the end of 2027
86
%
Meibomian gland dysfunction accounts for 86% of dry eyes
Products
Products
HWBIO® MeiboReviveTM Vectored Thermal Pulsation System
HWBIO® MeiboRevive Vectorted™ Thermal Pulsation System（S36） consists of a console and a disposable sterile treatment device.It uses local heating and compression on the eyelid area to treat dry eye caused by meibomian gland dysfunction (MGD).
HWBIO® MeiboRevive ™ Vectored Thermal Pulsation System consists of a main console, and a disposable, sterile interocular treatment instrument - the "OcuReviver".
It uses localized electronic heating and compression on the eyelid area to treat dry eye caused by meibomian gland dysfunction.
Morbidity Of Dry Eye Disease
Morbidity Of Dry Eye Disease
Global prevalence of dry eye disease was estimated at 11.59%. For symptomatic disease, the estimate was 9.12%, with women 9.5% and men 6.8% ; prevalence was lowest in North America, 4.6% and highest in Africa, 47.9%. For signs, prevalence was 35.2% , with woman 34.7% and men 37.6% ; North America showed the lowest regional prevalence, 3.5%, with Eastern Asia the highest, 42.8%.
Global prevalence of dry eye disease was estimated at 11.59%. For symptomatic disease, the estimate was 9.12%, with women 9.5% and men 6.8% ; prevalence was lowest in North America, 4.6% and highest in Africa, 47.9%. For signs, prevalence was 35.2% , with woman 34.7% and men 37.6% ; North America showed the lowest regional prevalence, 3.5%, with Eastern Asia the highest, 42.8%.
Papas EB. The global prevalence of dry eye disease: A Bayesian view. Ophthalmic Physiol Opt. 2021 Nov;41(6):1254-1266. doi: 10.1111/opo.12888. Epub 2021 Sep 21. PMID: 34545606.
CONTACT US
Add: 1355 Chengbei Road, Jiading District, Shanghai
Email: hwbio@hwbiosciences.com
CONTACT US
Add: 1355 Chengbei Road, Jiading District, Shanghai
Email: hwbio@hwbiosciences.com
SHARE US
SHARE US
点击右上角
分享给朋友吧
Copyright © HW Biosciences. All rights reserved
HW Biosciences Co., Ltd.
